Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States

Bart M Demaerschalk, Todd R. Yip

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background and Purpose - Health economic analyses of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke reveal a substantial cost savings. Unfortunately, tPA is vastly underused. The purpose of this study was to determine the economic impact of increasing tPA utilization in the United States. Methods - Annual incidence estimates of ischemic stroke in the United States and individual states were obtained. The proportion of all ischemic stroke patients who receive tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of the healthcare system over a time period of 1 year. With incremental increases in the proportion of all ischemic stroke patients treated with tPA, potential cost savings were recalculated. The outcomes are expressed in dollars saved annually. Results - There are 616 000 new ischemic stroke patients annually. A $600 net cost savings is associated with each tPA-treated patient. Currently, an estimated 2% of all ischemic stroke patients receive tPA. If the proportion was increased to 4, 6, 8, 10,15, or 20%, the realized cost savings would be approximately $15, 22, 30, 37, 55, and 74 million, respectively. Conclusions - If even small manageable increases in the proportion of all ischemic stroke patients who received tPA were achieved, it would result in an enormous realized savings for America's healthcare system.

Original languageEnglish (US)
Pages (from-to)2500-2503
Number of pages4
JournalStroke
Volume36
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Tissue Plasminogen Activator
Stroke
Economics
Cost Savings
Delivery of Health Care
Annual Reports
Incidence
Health

Keywords

  • Acute stroke
  • Economics
  • TPA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. / Demaerschalk, Bart M; Yip, Todd R.

In: Stroke, Vol. 36, No. 11, 11.2005, p. 2500-2503.

Research output: Contribution to journalArticle

@article{9a005ab8dd9e4a538fdc689c6ce0ab4f,
title = "Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States",
abstract = "Background and Purpose - Health economic analyses of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke reveal a substantial cost savings. Unfortunately, tPA is vastly underused. The purpose of this study was to determine the economic impact of increasing tPA utilization in the United States. Methods - Annual incidence estimates of ischemic stroke in the United States and individual states were obtained. The proportion of all ischemic stroke patients who receive tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of the healthcare system over a time period of 1 year. With incremental increases in the proportion of all ischemic stroke patients treated with tPA, potential cost savings were recalculated. The outcomes are expressed in dollars saved annually. Results - There are 616 000 new ischemic stroke patients annually. A $600 net cost savings is associated with each tPA-treated patient. Currently, an estimated 2{\%} of all ischemic stroke patients receive tPA. If the proportion was increased to 4, 6, 8, 10,15, or 20{\%}, the realized cost savings would be approximately $15, 22, 30, 37, 55, and 74 million, respectively. Conclusions - If even small manageable increases in the proportion of all ischemic stroke patients who received tPA were achieved, it would result in an enormous realized savings for America's healthcare system.",
keywords = "Acute stroke, Economics, TPA",
author = "Demaerschalk, {Bart M} and Yip, {Todd R.}",
year = "2005",
month = "11",
doi = "10.1161/01.STR.0000185699.37843.14",
language = "English (US)",
volume = "36",
pages = "2500--2503",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States

AU - Demaerschalk, Bart M

AU - Yip, Todd R.

PY - 2005/11

Y1 - 2005/11

N2 - Background and Purpose - Health economic analyses of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke reveal a substantial cost savings. Unfortunately, tPA is vastly underused. The purpose of this study was to determine the economic impact of increasing tPA utilization in the United States. Methods - Annual incidence estimates of ischemic stroke in the United States and individual states were obtained. The proportion of all ischemic stroke patients who receive tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of the healthcare system over a time period of 1 year. With incremental increases in the proportion of all ischemic stroke patients treated with tPA, potential cost savings were recalculated. The outcomes are expressed in dollars saved annually. Results - There are 616 000 new ischemic stroke patients annually. A $600 net cost savings is associated with each tPA-treated patient. Currently, an estimated 2% of all ischemic stroke patients receive tPA. If the proportion was increased to 4, 6, 8, 10,15, or 20%, the realized cost savings would be approximately $15, 22, 30, 37, 55, and 74 million, respectively. Conclusions - If even small manageable increases in the proportion of all ischemic stroke patients who received tPA were achieved, it would result in an enormous realized savings for America's healthcare system.

AB - Background and Purpose - Health economic analyses of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke reveal a substantial cost savings. Unfortunately, tPA is vastly underused. The purpose of this study was to determine the economic impact of increasing tPA utilization in the United States. Methods - Annual incidence estimates of ischemic stroke in the United States and individual states were obtained. The proportion of all ischemic stroke patients who receive tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of the healthcare system over a time period of 1 year. With incremental increases in the proportion of all ischemic stroke patients treated with tPA, potential cost savings were recalculated. The outcomes are expressed in dollars saved annually. Results - There are 616 000 new ischemic stroke patients annually. A $600 net cost savings is associated with each tPA-treated patient. Currently, an estimated 2% of all ischemic stroke patients receive tPA. If the proportion was increased to 4, 6, 8, 10,15, or 20%, the realized cost savings would be approximately $15, 22, 30, 37, 55, and 74 million, respectively. Conclusions - If even small manageable increases in the proportion of all ischemic stroke patients who received tPA were achieved, it would result in an enormous realized savings for America's healthcare system.

KW - Acute stroke

KW - Economics

KW - TPA

UR - http://www.scopus.com/inward/record.url?scp=27644486679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644486679&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000185699.37843.14

DO - 10.1161/01.STR.0000185699.37843.14

M3 - Article

C2 - 16224087

AN - SCOPUS:27644486679

VL - 36

SP - 2500

EP - 2503

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -